Peter Gasser1, Katharina Kirchner2, Torsten Passie3. 1. Medical Office for Psychiatry and Psychotherapy, Solothurn, Switzerland pgasser@gmx.net. 2. Psychologist MSc, Dietikon, Switzerland. 3. Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
Abstract
OBJECTIVE: A recently published study showed the safety and efficacy of LSD-assisted psychotherapy in patients with anxiety associated with life-threatening diseases. Participants of this study were included in a prospective follow-up. METHOD: 12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview. A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and lasting psychological changes. RESULTS: None of the participants reported lasting adverse reactions. The significant benefits as measured with the STAI were sustained over a 12-month period. In the QCA participants consistently reported insightful, cathartic and interpersonal experiences, accompanied by a reduction in anxiety (77.8%) and a rise in quality of life (66.7%). Evaluations of subjective experiences suggest facilitated access to emotions, confrontation of previously unknown anxieties, worries, resources and intense emotional peak experiences à la Maslow as major psychological working mechanisms. The experiences created led to a restructuring of the person's emotional trust, situational understanding, habits and world view. CONCLUSIONS:LSD administered in a medically supervised psychotherapeutic setting can be safe and generate lasting benefits in patients with a life-threatening disease. Explanatory models for the therapeutic effects of LSD warrant further study.
RCT Entities:
OBJECTIVE: A recently published study showed the safety and efficacy of LSD-assisted psychotherapy in patients with anxiety associated with life-threatening diseases. Participants of this study were included in a prospective follow-up. METHOD: 12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview. A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and lasting psychological changes. RESULTS: None of the participants reported lasting adverse reactions. The significant benefits as measured with the STAI were sustained over a 12-month period. In the QCA participants consistently reported insightful, cathartic and interpersonal experiences, accompanied by a reduction in anxiety (77.8%) and a rise in quality of life (66.7%). Evaluations of subjective experiences suggest facilitated access to emotions, confrontation of previously unknown anxieties, worries, resources and intense emotional peak experiences à la Maslow as major psychological working mechanisms. The experiences created led to a restructuring of the person's emotional trust, situational understanding, habits and world view. CONCLUSIONS: LSD administered in a medically supervised psychotherapeutic setting can be safe and generate lasting benefits in patients with a life-threatening disease. Explanatory models for the therapeutic effects of LSD warrant further study.
Authors: M Kaelen; F S Barrett; L Roseman; R Lorenz; N Family; M Bolstridge; H V Curran; A Feilding; D J Nutt; R L Carhart-Harris Journal: Psychopharmacology (Berl) Date: 2015-08-11 Impact factor: 4.530
Authors: Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak Journal: Ther Adv Psychopharmacol Date: 2016-03-18
Authors: A V Lebedev; M Kaelen; M Lövdén; J Nilsson; A Feilding; D J Nutt; R L Carhart-Harris Journal: Hum Brain Mapp Date: 2016-05-06 Impact factor: 5.038
Authors: Kuglae Kim; Tao Che; Ouliana Panova; Jeffrey F DiBerto; Jiankun Lyu; Brian E Krumm; Daniel Wacker; Michael J Robertson; Alpay B Seven; David E Nichols; Brian K Shoichet; Georgios Skiniotis; Bryan L Roth Journal: Cell Date: 2020-09-17 Impact factor: 41.582
Authors: Simon D Brandt; Pierce V Kavanagh; Brendan Twamley; Folker Westphal; Simon P Elliott; Jason Wallach; Alexander Stratford; Landon M Klein; John D McCorvy; David E Nichols; Adam L Halberstadt Journal: Drug Test Anal Date: 2017-07-27 Impact factor: 3.345